Experimental and new investigational drugs for the treatment of uterine fibroids

Giulio Evangelisti,Simone Ferrero,Umberto Perrone,Claudio Gustavino,Eugenio Volpi,Alberto Izzotti,Fabio Barra
DOI: https://doi.org/10.1080/13543784.2024.2343786
2024-04-18
Expert Opinion on Investigational Drugs
Abstract:Introduction Uterine fibroids, the most prevalent benign tumors among reproductive-age women, pose treatment challenges that range from surgical interventions to medical therapies for symptom control. Progestins and estroprogestins effectively manage uterine bleeding by suppressing dysfunctional endometrium over fibroids. While GnRH agonists represent a crucial milestone in symptom treatment, their prolonged use results in menopausal-like symptoms and irreversible bone mineral density loss. Advancements in understanding fibroid pathophysiology have prompted the exploration of new compounds to overcome current therapy limitations.
pharmacology & pharmacy
What problem does this paper attempt to address?